To identify and address specific oncology outcomes research issues and to develop recommendations to address these issues.
The field of oncology outcomes research is complicated by the diversity of diseases within oncology, the rapidly changing nature of treatments, and the complexities of measuring cost, and quality of life - patient reported outcomes. As such, oncology outcomes research constitutes a unique segment of outcomes research, one that requires specific clinical and methodological knowledge for its proper conduct.
- Clinical Evidence for Health Technology Assessment in Oncology, Are We Going Backwards? Where Are We Going With Single-Arm Trials?
- Click here to read an interview with Sorrel Wolowacz (Head, European Health Economics, RTI Health Solutions, UK) where she discusses the ISPOR Europe 2022 Issue Panel by the ISPOR Oncology Special Interest Group on the use of single-arm trials in oncology, and evidence generation for health technology assessment (HTA) decisions.
Haitham Tuffaha, MSc, MBA, RPh, PhD, BSc
Health Technology Assessment Leader, University of Queensland, Centre for the Business and Economics of Health
Brisbane, QLD, Australia
Sang Kyu Cho, PharmD, MPH
Associate, Analysis Group
Boston, MA, United States
Abeer Al Rabayah, MSc, MBA, BSc
Head, Center for Drug Policy & Technology Assessment, King Hussein Cancer Center
Dem Aliaj, MSc
MSc, University of Lucerne
Kriens, LU, Switzerland
Brittany Carson, PhD, MHEcon, BSc
Medical Director, ApotheCom
New York, NY, United States
AD Market Access, MSD
Singapore, 01, Singapore
Christopher Graham, MS, BS
Senior Director, Health Economics, RTI Health Solutions
Durham, NC, United States
Min-Hua Jen, PhD
Director, Eli Lilly
Uxbridge, LON, United Kingdom
Sorrel Wolowacz, PhD
Head, EU Health Economics, RTI Health Solutions
Manchester, United Kingdom
Questions or ideas? Please send an email to Oncologysig@ISPOR.org